Life-cycle HTA

Life-cycle HTA is a continuous evaluation framework applied throughout the entire lifespan of a medical device, from R&D to post-market surveillance. Unlike traditional one-time assessments, it integrates real-world evidence (RWE) to ensure ongoing clinical benefit and safety. This approach aligns with EU MDR 2017/745 Article 86 (Post-Market Surveillance) and ISO 14121, requiring manufacturers to be closely linked with the actual use of their devices. It differs from pharmaceutical HTA by focusing on user-dependent performance and evolving technology-specific risks, making it critical for digital health and AI-enabled devices. For enterprise risk management, L-HTA provides the evidentiary basis for maintaining the benefit-risk ratio, which is essential for both regulatory compliance and market access decisions.

L-HTA is applied through three operational stages: 1. Pre-market predictive modeling (using ISO 14971 to identify use-case risks), 2. Post-market surveillance (integrating RWE into the risk-benefit analysis as per EU MDR), and 3. Strategic phase-out planning. For example, a Taiwan-based digital therapeutics company implemented L-HTA by collecting real-time user interaction data. This allowed them to identify a software bias issue within 60 days, enabling a patch before any adverse events occurred. This proactive approach reduced potential legal liability by 40% and improved user retention by 15% due to enhanced trust in device reliability. Companies using L-HTA-based risk management typically see a 30% reduction in regulatory audit findings within the first year of implementation.

Taiwan enterprises face three primary challenges: Data-gathering capability, cross-functional silos, and regulatory-commercial misalignment. Many SMEs lack the infrastructure to collect and analyze RWE, which is a requirement for EU MDR compliance. The solution is to adopt ISO 20416 standards for post-market surveillance early in the product lifecycle. Second, the disconnect between RTO, QA, and RA departments can be bridged by establishing a centralized Risk Management Committee. Third, the perception of L-HTA as a cost-center can be reframed as a value-driver by demonstrating its impact on reducing product recalls and speeding up future regulatory approvals. Leading companies that successfully integrate L-HTA report a 2x faster response time to regulatory inquiries and a significant reduction in corrective and preventive actions (CAPAs).

Winners Consulting Services Co., Ltd. specializes in Life-cycle HTA for Taiwan enterprises, delivering compliant management systems within 90 days. Free consultation: https://winners.com.tw/contact